UBS Maintains Buy on Elevance Health, Raises Price Target to $605
UBS analyst A.J. Rice maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $585 to $605.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments